このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

既にワクチン接種を受けた成人における、経鼻および吸入経路によるSARS-CoV-2スパイクワクチンをコードするChAd36ベクターOCU500の安全性および免疫原性試験

既にワクチンを接種した成人を対象とした、経鼻および吸入経路による次世代SARS-CoV-2ブースターワクチンOCU500(SARS-CoV-2スパイクをコードするChAd36ベクター)の第1相オープンラベル安全性・免疫原性試験

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults.

調査の概要

状態

積極的、募集していない

介入・治療

詳細な説明

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults. Secondary objectives include evaluating systemic anti-Spike humoral responses, nasal mucosal Immunoglobulin A (IgA) and Immunoglobulin G (IgG) responses, and immune responses toward vectors.

研究の種類

介入

入学 (実際)

83

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Georgia
      • Decatur、Georgia、アメリカ、30030-1705
        • The Hope Clinic of Emory University
    • Maryland
      • Baltimore、Maryland、アメリカ、21201-1509
        • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115-6110
        • Brigham and Women's Hospital
    • Missouri
      • St Louis、Missouri、アメリカ、63104-1015
        • Saint Louis University Center for Vaccine Development
    • Texas
      • Galveston、Texas、アメリカ、77555-0435
        • University of Texas Medical Branch

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~64年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Provides written informed consent before initiation of any study procedures.

  2. Able to understand and agree to comply with planned study procedures and be available for all study visits.

  3. Non-pregnant adults, 18 through 64 years of age at the time of study product administration.

  4. Participants of childbearing potential* must agree to use or have practiced true abstinence** or use at least one acceptable primary form of contraception.***

    *These criteria apply to females who are in a heterosexual relationship and are of childbearing potential. Not of childbearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation/salpingectomy).

    **True abstinence is 100 percent of the time, no sexual intercourse (penis enters the vagina). Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods.

    ***Acceptable forms of primary contraception include a monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more before the participant's study product administration, a copper intrauterine device, a levonorgestrel-releasing intrauterine device, a progestin-only oral contraceptive pill, a depot medroxyprogesterone injection, or a progestin implant. Combined hormonal contraceptives containing estrogen, including combined oral contraceptive pills, transdermal patches, and vaginal rings, are not acceptable for this trial. Must have used at least one acceptable primary form of contraception for at least 30 days before study product administration and agree to continue at least one acceptable primary form of contraception through 60 days after study product administration.

  5. Participants of childbearing potential must have a negative urine pregnancy test at screening and within 24 hours before study product administration.

  6. In general, good health.*

    *As determined by medical history and physical examination, including vital signs, to evaluate acute or ongoing chronic medical diagnoses/conditions that have been present for at least 90 days, which would affect the assessment of participant safety. Chronic medical diagnoses/ conditions should be stable for the last 30 days (i.e., no hospitalization, ER, or urgent care for the condition). This includes no change in chronic prescription medication, dose, or frequency due to deterioration of the chronic medical diagnosis or condition within the 30 days preceding the study product administration. Any prescription change that is due to a change of health care provider, insurance company, etc., or done for financial reasons, and in the same class of medication, will not be considered a deviation of this inclusion criterion. Participants may be on chronic or as-needed (prn) medications if, in the opinion of the participating site PI or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity.

  7. Receipt of a complete primary COVID-19 vaccine series and at least one booster* with last vaccination at least 16 weeks before study product administration.

    *Booster may be either homologous or heterologous to the primary vaccine series. It must be an FDA-authorized/licensed vaccine, though doses may have been received as part of a clinical trial.

  8. Clinical screening laboratory evaluations are within normal reference ranges or grade 1 with no clinical significance (NCS) per investigator discretion.*

    *(White Blood Cells [WBCs] with differential [diff], hemoglobin [Hgb], platelets [PLTs], PTT, PT, Alanine Transaminase [ALT], Aspartate Transaminase [AST], Creatinine [Cr], Alkaline Phosphatase [ALP], Total Bilirubin [T. Bili]). ALT, AST, ALP, T. Bili, and creatinine values that are below the reference range will not be exclusionary, as these values below the reference range are clinically insignificant.

  9. Must agree to have samples stored for secondary research.

  10. Must complete a Test of Understanding (ToU) before enrollment by answering 90 percent of questions correctly at least once in 3 attempts.

Exclusion Criteria:

  1. Positive SARS-CoV-2 PCR at screening.

  2. Abnormal vital signs (Grade 1 or higher).*

    *Grade 1 or higher is equivalent to: Systolic blood pressure (SBP) = 141 mmHg or = 89 mmHg Diastolic blood pressure (DBP) = 91 mmHg Heart rate (HR) is = 101 beats per minute or = 54 beats per minute Oral temperature = 38.0 degrees Celsius (100.4 degrees Fahrenheit)

  3. History of SARS-CoV-2 infection within the prior 16 weeks OR receipt of any COVID-19 vaccine within the prior 16 weeks before study product administration.

  4. Participant who is pregnant or breastfeeding or less than 12 weeks post partum at the time of study product administration.

  5. Participant has donated blood or plasma within 4 weeks prior to study product administration, or does not agree to refrain from blood or plasma donation until Day 181.

  6. Receipt of antibody or blood-derived products within 90 days before study product administration.

  7. Any significant medical or psychiatric diseases or any other condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation.*

    *Significant self-reported or medically reported medical or psychiatric conditions include, but are not limited to drug or alcohol abuse within 6 months of enrollment, significant kidney disease, liver disease, history of hematologic malignancies, ongoing malignancy or recent diagnosis of malignancy in the last five years, excluding treated basal cell and squamous cell carcinoma of the skin, and cervical carcinoma in situ, which are allowed.

  8. Any respiratory disease, including but not limited to chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis, etc.

  9. Neurological or neurodevelopmental conditions.*

    *These conditions include: history of Bell's palsy, history of four or more migraine headaches in the past 12 months that interfered with normal daily activity or any migraine headache in the past 5 years that required emergency or inpatient medical care, epilepsy, seizures in the last 5 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, myelopathy, peripheral neuropathy, encephalomyelitis, transverse myelitis, stroke or transient ischemic attack, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, or Alzheimer's disease.

  10. Cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease), including any history of myocarditis or pericarditis, or uncontrolled cardiac arrhythmia.

  11. Any autoimmune disease, including hypothyroidism without a defined non-autoimmune cause.

  12. Any significant nasal or upper airway disease.*

    *Including, but not limited to, being prone to epistaxis, a history of inflammatory rhinitis (including allergic rhinitis) that requires daily medications, cochlear implants, head/neck radiation history, anosmia/dysosmia, conditions that require prescription or over the counter intranasal medication (intermittent use will be allowed if no use occurred for 30 days before study product administration and participant agrees to not use intranasal medication (other than steroids) for 30 days after study product administration and to not use intranasal steroids for 6 months after study product administration), and certain ear, nose and throat (ENT) conditions, including significant upper airway/nasopharyngeal disease or abnormal anatomy such as CSF leak.

  13. Has an acute illness, as determined by the site Principal Investigator or appropriate sub-investigator within 72 hours before study product administration.*

    *An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the participating site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.

  14. Has a positive test result for hepatitis B surface antigen, hepatitis C virus RNA (by reflex testing), or human immunodeficiency virus (HIV) antigen/antibody test at screening.

  15. Has any confirmed or suspected immunosuppressive or immunodeficient state, such as asplenia, recurrent severe infections, and chronic* immunosuppressant medication within the past 6 months.**

    *Chronic meaning more than 14 continuous days.

    **Ophthalmic and topical steroids are allowed, see exclusions 12 and 21 for intranasal steroids.

  16. Has received any investigational product within 60 days, or 5 half-lives, whichever is longer, before study product administration; or is planning to receive one during the study.

  17. Has a history of hypersensitivity or severe allergic reaction* to any previous licensed or unlicensed vaccine or to the candidate vaccine components.

    *e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction

  18. History of chronic idiopathic urticaria.

  19. Received or plans to receive licensed inactivated/subunit vaccine within 14 days of study product administration or live vaccine within 28 days of study product administration.

  20. Plan to receive a COVID-19 vaccine within the 180 days following study product administration.

  21. Regular use of intranasal medications, including steroids.*

    *Participant must have had no intranasal medication use for 30 days before study product administration and plans not to use intranasal medications for 30 days after study product administration for medications other than steroids, and for 6 months after study product administration for intranasal steroids (including over-the-counter fluticasone).

  22. History of smoking within three months before enrollment.*

    *Including cigarettes, smokeless and other tobacco products, e-cigarettes (to include vaping and Juuling products), marijuana, nicotine gum, and nicotine lozenges.

  23. Use of intranasal illicit drugs in the 5 years before study product administration or plans to use during the study.

  24. Planned international travel between study product administration and Day 29.

  25. Previous receipt of any adenovirus-vector vaccine by the intranasal or aerosol routes.

  26. Bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following Intramuscular injections or venipuncture.

  27. Recent (within 3 months of study product administration): major surgery, >=3 days immobility, chronic infection, or head trauma that may increase thrombosis risk.*

    *Major surgery is either abdominal or vascular, or orthopedic surgery, and immobility implies bed rest.

  28. History of venous or arterial thrombosis or any known thrombophilic condition, including heparin-induced thrombocytopenia (HIT) or thrombosis.

  29. BMI >/= 40kg/m^2

  30. Current/planned systemic estrogen therapy, except stable transdermal estradiol, from 30 days pre-dose through end of study participation. Low-dose vaginal estrogen is permitted.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

実験的:Arm 2

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

実験的:Arm 3

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

実験的:Arm 4

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
異常な臨床安全研究所の有害事象(AE)の発生。
時間枠:8日目まで
8日目まで
特別な関心のある有害事象(AESI)の発生。
時間枠:研究製品投与後6か月間を通して
研究製品投与後6か月間を通して
医療上対応が必要な有害事象(MAAEs)の発生。
時間枠:研究製品投与後6か月間を通じて
研究製品投与後6か月間を通じて
新規発症性慢性疾患(NOCMCs)の発生。
時間枠:研究製品投与後6ヶ月間
研究製品投与後6ヶ月間
重篤な有害事象(SAE)の発生。
時間枠:研究製品投与後6ヶ月間
研究製品投与後6ヶ月間
募集された局所的な有害事象(AE)の発生。
時間枠:8日目まで
8日目まで
Occurrence of solicited systemic adverse events (AEs).
時間枠:8日目まで
8日目まで
自発的な有害事象(AE)の発生。
時間枠:29日目まで
29日目まで

二次結果の測定

結果測定
時間枠
抗ベクター抗体のレベル
時間枠:1日目から91日目まで
1日目から91日目まで
SARS-CoV-2抗スパイク鼻粘膜結合免疫グロブリンA(IgA)
時間枠:第1日目から第181日目
第1日目から第181日目
SARS-CoV-2 抗スパイク鼻腔粘膜結合免疫グロブリンG(IgG)
時間枠:第1日から第181日
第1日から第181日
SARS-CoV-2 抗スパイク血清結合免疫グロブリンA(IgA)抗体
時間枠:1日目から181日目
1日目から181日目
SARS-CoV-2抗スパイク血清結合免疫グロブリンG(IgG)抗体
時間枠:1日目から181日目まで
1日目から181日目まで
SARS-CoV-2 抗スパイク血清中和抗体
時間枠:第1日目から第181日目まで
第1日目から第181日目まで

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月26日

一次修了 (推定)

2027年4月29日

研究の完了 (推定)

2027年11月1日

試験登録日

最初に提出

2026年4月10日

QC基準を満たした最初の提出物

2026年4月10日

最初の投稿 (実際)

2026年4月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年4月14日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する